Boehringer Ingelheim and Circuit Therapeutic’s collaboration to discover novel obesity drug

Boehringer Ingelheim and Circuit Therapeutics have announced a second collaboration using Circuit’s proprietary optogenetics technology platform. This new three-year collaboration will focus on investigating metabolic disorders with the aim of developing novel medicines to improve the treatment of obesity and associated diseases. The prior collaboration between the two companies focused on the discovery of new treatments for neuropsychiatric disorders.

Boehringer Ingelheim is a leader in cardiometabolic disease research and development and has ambitious strategic goals in diabetes and metabolism. The new collaboration is intended to broaden Boehringer Ingelheim’s pipeline in this area. Eating disorders are among the major contributing factors to the development of overweight and obesity which are major risk factors for type 2 diabetes, heart disease, high blood pressure, and other health problems.